



March 20, 2023

Company Name: AnGes Inc.

Presentative: Ei Yamada, President & CEO

**Notice of Agreement with Shionogi regarding cooperation  
in domestic Phase II clinical trials of NF-κB decoy oligo DNA  
for the treatment of chronic intervertebral disc low back pain**

AnGes Inc. today announced that its Board of Directors has resolved to enter into an agreement with Shionogi & Co., Ltd. ("Shionogi") for cooperation in the Phase II clinical trials of NF-κB decoy oligo DNA for chronic discogenic low back pain in Japan.

1. Background of this Decision

In the "Announcement of Decision on Domestic Development of NF-κB Decoy Oligo DNA for the Treatment of Chronic Intervertebral Disc Lumbago" disclosed on January 30, 2023, we announced that we will conduct Phase II clinical trials of our development product, NF-κB decoy oligo DNA, in Japan. We have decided to enter into an agreement with Shionogi for cooperation in this Phase II clinical trial. We expects to receive a portion of the clinical trial costs from Shionogi as a result of this agreement, but the amount has not yet been finalized.

Under the terms of the agreement, Shionogi and AnGes will discuss the conduct of subsequent Phase III clinical trials based on the results of the Phase II clinical trials.

2. About Shionogi

Name	Shionogi & Co.,Ltd.
Location	1-8, Doshomachi 3-chome, Chuo-ku, Osaka-shi, Osaka
Representative	Isao Teshirogi, Representative Director, Chairman and President
Business	Pharmaceutical Business

3. About NF-κB Decoy Oligo DNA

NF-κB is a major transcription factor that is activated when cells are exposed to external stimuli such as oxidative stress caused by reactive oxygen species to induce inflammatory and immune responses.

NF-κB decoy oligo DNA binds to this NF-κB transcription factor and inhibits the release of inflammatory cytokines (bioactive substances secreted by cells), and is expected to be effective in the treatment of various diseases caused by excessive inflammatory and immune responses. Until now, treatment for chronic discogenic lumbago has focused on symptomatic therapy with anti-inflammatory and analgesic agents, but NF-κB decoy oligo DNA suppresses the activation of substances that cause excessive inflammatory and immune responses, and is expected to improve patients' quality of life in addition to its strong analgesic effect.

(Note)This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.



#### 4. Development history of NF- $\kappa$ B decoy oligo DNA

NF- $\kappa$ B decoy oligo DNA began late-stage Phase I clinical trials in patients with discogenic low back pain in the U.S. in February 2018, and results obtained in April 2021 confirmed a high level of safety with no serious adverse events (SAEs). The product was also evaluated in an exploratory data set for efficacy, with significant reductions in low back pain beginning early in the course of treatment and continuing until 12 months post-treatment.

Based on the above results, we have decided to conduct a Phase II clinical trial in Japan, as there are many patients with chronic discogenic low back pain in Japan, and we believe that commercialization of the product in Japan is feasible.

#### 5. Future outlook

The impact of the conclusion of this agreement on the Company's consolidated financial forecast for the current fiscal year is expected to be immaterial. If any matters arise that should be disclosed in the future, we will promptly notify you.

(Note) This document has been translated from the Japanese original for reference purposes only.  
In the event of any discrepancy between this translation and the Japanese original, the original shall prevail.